Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.
Start 7-day free trial → Log in

Odetiglucan · BTH-1677

Other · Immune activation, directed at complement receptor 3 (CR3) (ITGAM) and Fc gamma receptor IIA (CD32A) (FCGR2A) · developed by HiberCell

Phase 1 Most advanced trial (none active)
1 Registered trials

What is Odetiglucan?

Odetiglucan is a soluble beta-1,3/1,6 glucan from the cell wall of a Saccharomyces cerevisiae yeast strain, acting as a pathogen-associated molecular pattern. It binds innate immune effector cells through CR3 and CD32A, activating them and repolarizing the tumor microenvironment to enhance anti-tumor immune responses. It is being studied in metastatic pancreatic adenocarcinoma.

Summary written with AI from the sources listed at the end of this page.

At a glance

Also known as
BTH-1677, Imprime, Imprime PGG
Drug type
Other
Targets
complement receptor 3 (CR3) (ITGAM), Fc gamma receptor IIA (CD32A) (FCGR2A)
Mechanism
Immune activation, directed at complement receptor 3 (CR3) (ITGAM) and Fc gamma receptor IIA (CD32A) (FCGR2A)
Pathways
innate immune cell activation, macrophage M2-to-M1 repolarization, antigen presenting cell maturation, CD4 and CD8 T-cell expansion, IFN-gamma production
Therapy area
Oncology
Developer
HiberCell, Inc.
In trials of
CLDX
FDA status
Investigational, not approved in the US. Most advanced trial: Phase 1
UNII
Q6X9CNN54X

🧪 Clinical trials

TrialPhaseConditionStatusSponsor
NCT05484011 Phase 1 Metastatic Pancreatic Adenocarcinoma Terminated CLDX

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

Metastatic Pancreatic Adenocarcinoma

Other drugs acting on ITGAM / FCGR2A

GB1275 Phase 1

Sources

Updated Oct 11, 2026.

Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.